抗刺突黏膜IgA对SARS-CoV-2奥密克戎感染的保护作用。 - Suppr

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

作者信息

Havervall Sebastian, Marking Ulrika, Svensson Julia, Greilert-Norin Nina, Bacchus Philip, Nilsson Peter, Hober Sophia, Gordon Max, Blom Kim, Klingström Jonas, Åberg Mikael, Smed-Sörensen Anna, Thålin Charlotte

机构信息

Karolinska Institutet, Stockholm, Sweden.

Swedish Armed Forces, Umeå, Sweden.

出版信息

N Engl J Med. 2022 Oct 6;387(14):1333-1336. doi: 10.1056/NEJMc2209651. Epub 2022 Sep 14.

DOI:10.1056/NEJMc2209651

PMID:36103621

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9511632/

Abstract

摘要

相似文献

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

N Engl J Med. 2022 Oct 6;387(14):1333-1336. doi: 10.1056/NEJMc2209651. Epub 2022 Sep 14.

Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.

Signal Transduct Target Ther. 2021 Jan 29;6(1):35. doi: 10.1038/s41392-021-00478-7.

Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.

Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28.

Neutralizing SARS-CoV-2.

Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.

Cell Rep Med. 2022 Jan 24;3(2):100528. doi: 10.1016/j.xcrm.2022.100528. eCollection 2022 Feb 15.

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.

J Allergy Clin Immunol. 2021 Mar;147(3):876-877. doi: 10.1016/j.jaci.2020.12.003. Epub 2020 Dec 17.

Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.

Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.

The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time.

PLoS One. 2022 Mar 9;17(3):e0249723. doi: 10.1371/journal.pone.0249723. eCollection 2022.

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.

Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.

Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.

Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.

引用本文的文献

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.

Nat Commun. 2025 Aug 7;16(1):7281. doi: 10.1038/s41467-025-62698-7.

XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease.

Vaccines (Basel). 2025 Jul 16;13(7):759. doi: 10.3390/vaccines13070759.

Lung-resident SARS-CoV-2 peptide-specific immune responses in perfused 3D human lung explant models.

Front Bioeng Biotechnol. 2025 Jul 8;13:1587080. doi: 10.3389/fbioe.2025.1587080. eCollection 2025.

Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice.

Sci Rep. 2025 Jul 7;15(1):24224. doi: 10.1038/s41598-025-06880-3.

Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial.

Sci Adv. 2025 Jul 4;11(27):eadw0896. doi: 10.1126/sciadv.adw0896.

Immunomodulatory effects of gut microbiota on vaccine efficacy against respiratory pathogens.

Front Immunol. 2025 Jun 3;16:1618921. doi: 10.3389/fimmu.2025.1618921. eCollection 2025.

Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk.

Pathog Immun. 2025 May 22;10(2):97-121. doi: 10.20411/pai.v10i2.799. eCollection 2025.

Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA.

Front Immunol. 2025 May 20;16:1571418. doi: 10.3389/fimmu.2025.1571418. eCollection 2025.

Immunological duet between CD4 T cells and B cells in the lung following an intranasal protein boost.

Nat Immunol. 2025 Jun;26(6):814-816. doi: 10.1038/s41590-025-02168-w.

Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies.

Cell Discov. 2025 May 20;11(1):49. doi: 10.1038/s41421-025-00800-5.

本文引用的文献

Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.

J Exp Med. 2022 Jul 4;219(7). doi: 10.1084/jem.20220638. Epub 2022 Jun 15.

Immune boosting by B.1.1.529 Omicron) depends on previous SARS-CoV-2 exposure.

Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841.

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.

Lancet Infect Dis. 2022 Jul;22(7):943-945. doi: 10.1016/S1473-3099(22)00362-0. Epub 2022 Jun 9.

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.

Viruses. 2022 Jan 19;14(2):187. doi: 10.3390/v14020187.

Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.

JCI Insight. 2021 Nov 22;6(22):e151463. doi: 10.1172/jci.insight.151463.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献